AUTOMATED CLOSED SYSTEM FOR DMSO REMOVAL FROM PERIPHERAL BLOOD STEM CELLS

Information

  • Research Project
  • 7054977
  • ApplicationId
    7054977
  • Core Project Number
    R43HL083669
  • Full Project Number
    1R43HL083669-01
  • Serial Number
    83669
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/1/2006 - 18 years ago
  • Project End Date
    1/31/2007 - 17 years ago
  • Program Officer Name
    BISHOP, TERRY ROGERS
  • Budget Start Date
    2/1/2006 - 18 years ago
  • Budget End Date
    1/31/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
  • Award Notice Date
    1/31/2006 - 18 years ago

AUTOMATED CLOSED SYSTEM FOR DMSO REMOVAL FROM PERIPHERAL BLOOD STEM CELLS

[unreadable] DESCRIPTION (provided by applicant): High dose chemotherapy followed by peripheral blood hematopoietic stem cell (PBSC) transplantation is frequently used for treating various hematologic malignancies. To facilitate this process, autologous PBSC are typically collected, cryopreserved and stored for some period of time. Current PBSC cryopreservation requires the use of molar concentrations of the cryoprotectant additive dimethyl sulfoxide (DMSO). Typically, frozen-thawed cells are transplanted back into patients along with DMSO. However, reinfusion of DMSO has long been associated with various adverse events, ranging from skin flushing, headache, fever, dyspnea, abdominal cramping, nausea, and diarrhea to more sever effects such as, hemolysis, cardiovascular symptoms and cerebrovascular ischemia leading to neurological events. These can result in increased morbidity, prolonged hospitalization, and increased treatment-related costs. Currently, when removal of DMSO is attempted, the procedures typically involve cell "washing" using centrifugation. These methods introduce mechanical forces and osmotic stress causing cell packing/clumping and potential significant cell loss. They also require additional laboratory staff as well, and take between 3 and 4 hours of work per patient, which makes the procedure more expensive and practically difficult for many institutions. Finally, it is difficult to keep the cells in a "closed" system during cell washing, which may lead to contamination. It is the goal of this proposal to refine and optimize an automated, portable, closed-system diffusion-driven washing device for use in clearance of DMSO from PBSC, to prevent infusion of DMSO into patients during clinical transplant without loss of cell numbers or cell functionality. In this Phase I research, the device will be optimized for effective clearance of DMSO from cell suspension solutions while allowing high cell recovery with maintenance of cell functional viability as assessed by in vitro clonogenic ability as well as engraftment in a NOD/SCID mouse model. [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    133734
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:133734\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GENERAL BIOTECHNOLOGY, LLC
  • Organization Department
  • Organization DUNS
    364285726
  • Organization City
    INDIANAPOLIS
  • Organization State
    IN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    46202
  • Organization District
    UNITED STATES